Looking to the Future: Biomarkers in the Management of Pancreatic Adenocarcinoma

International Journal of Molecular Sciences

Jennifer L. Spratlin¹ 

关键词: pancreatic adenocarcinoma;    hENT1;    hCNT3;    SPARC;    cDK;    biomarker;    clinical trials;    gemcitabine;    oxaliplatin;   

DOI  :  10.3390/ijms12095895

来源: mdpi

【 摘 要 】

The incidence and mortality of pancreas cancer converge. There has been little advancement in the treatment of pancreas cancer since the acceptance of gemcitabine as the standard therapy. Unfortunately, the efficacy of gemcitabine is dismal. While there is much discussion for the development of biomarkers to help direct therapy in this area, there is little action to move them into clinical practice. Herein, we review potential pancreatic cancer biomarkers and discuss the limitations in their implementation.

【 授权许可】

CC BY   
© 2011 by the authors; licensee MDPI, Basel, Switzerland.